Volume 15, Issue 58 (7-2006)                   JGUMS 2006, 15(58): 68-72 | Back to browse issues page

XML Persian Abstract Print


1- , ebrahimi_cardiology@yahoo.com
Abstract:   (9083 Views)
Abstract Introduction: Deep Vein thrombosis (DVT) is one of the most common vascular diseases, which affects millions of people around the world annually. The important complication of DVT, pulmonary emboli, can cause various dangers as well as mortality. Therefore correct and on time treatment helps patient’s life greatly. From time ago, standard or unfractionated heparin (UFH) has been the chosen treatment, but in recent years with the production of low molecular weight heparin (LMWH) and its specific advantages as compared to UFH, treating patients with LMWH instead of UFH has been presented. Objective: This study aims to compare the cost of LMWH and UFH in treatment of DVT. Materials and Methods: This cross- sectional study was conducted on 125 DVT hospitalized patients with DVT admitted to cardiac ward of Imam Reza Hospital in Mashhad between 2002 to 2004. Mean hospitalization days and hospital costs, nursing care, venous heparin prescription, routine tests and PTT test and also other costs such as serum therapy and … were extracted from patients’ medical files along with LMWH. Data was analyzed with SPSS software. Results: Mean hospital stay was 8.48±2.57 days. The average occupied bed was nearly 500 nights annually. Treatment cost with intravenous UFH and LMWH for each patient was 942080 Rials and 760000 Rials respectively. Conclusion: In attention to advantages of LMWH including economic benefits, decreased bed occupation, better personal and social function of patient, decreased complication and simple use, LMWH can be used in low risk patients instead of hospitalizing and treating with intravenous heparin.
Full-Text [PDF 143 kb]   (1907 Downloads)    
Review Paper: Research | Subject: Special
Received: 2014/01/14 | Accepted: 2014/01/14 | Published: 2014/01/14

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.